Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

Federal Trade Commission is discussing divestiture of Alza's Viadur, a Duros leuprolide product for advanced prostate cancer. TAP, Abbott's joint venture with Takeda, markets leuprolide in a depot formulation as Lupron. The companies say there is "significant interest" in Viadur from other pharmaceutical companies and they still expect to close the merger by the end of the year. Alza submitted an NDA for Viadur around the end of April. FTC is investigating TAP's marketing practices for Lupron

You may also be interested in...

Abbott Diagnostics Manufacturing Issues Could Decrease Alza Merger Value

Abbott's pending merger with Alza could give FDA leverage in discussions over quality control problems in Abbott's diagnostics business.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts